Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) Sees Significant Drop in Short Interest

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) was the recipient of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 2 shares, a decline of 98.5% from the June 15th total of 137 shares. Based on an average daily volume of 2,784 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the company are sold short.

Enzon Pharmaceuticals Price Performance

Shares of OTCMKTS:ENZN remained flat at $4.40 on Friday. 4,182 shares of the company’s stock were exchanged, compared to its average volume of 970. The company has a market cap of $3.26 million, a price-to-earnings ratio of -0.64 and a beta of -0.05. Enzon Pharmaceuticals has a 52 week low of $1.50 and a 52 week high of $11.10. The business has a fifty day simple moving average of $5.55 and a 200-day simple moving average of $5.68. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.01 and a quick ratio of 1.16.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last posted its quarterly earnings results on Monday, May 4th. The biotechnology company reported ($0.84) EPS for the quarter. The firm had revenue of $86.54 million for the quarter.

Enzon Pharmaceuticals Company Profile

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.